Private Equity/Venture Capital
-
Ms. Li’s experience includes providing legal services for:
- Hong Kong Asia Medical Group (a leading brand of cardiovascular medical care in Asia) in its $400 million Series D financing, which is the largest PE transaction of the year in China’s medical service field.
- ImmuneOnco (anti-tumor biotechnology) in its nearly $100 million cross-round financing.
- JLSemi (network communication chip design) in completing multiple rounds of equity financing with a total of more than $100 million and cross-border investment projects, as well as providing ongoing legal advisory services.
- Northern Light Venture Capital in its early round of VC investment in a number of high-end manufacturing and new material companies (such as AROMEM).
- Equity financings of chip startups such as AM Microelectronics and GLS, and serves as their long-term legal advisor.
- Huagai Capital's lead investment in MindRank (AI pharmaceuticals) in a Series A investment exceeding RMB 100 million.
- Linkzill (biological chips) in its early-stage financing and serves as its long-term legal advisor.
- Provided LDD and negotiation of transaction documents for PE investment projects of investment firms such as Huagai Capital, Shanjin Capital, Haoyue Capital, Lake Bleu Capital, and Northern Light Venture Capital.
- NewMed(heart valve replacement) in its Series C financing exceeding $100 million.
- Stphibio (Car-T cell therapy) in its Series A financing of several hundred million RMB from renowned investors including Shenzhen Venture Capital and VMS.
- GSR Ventures' dollar fund in its early-stage investment in Cloudpick (AI unmanned technology).
- TiLiGH (multi-omics oncology early screening) in multiple rounds of financing and serves as its long-term legal advisor.
- YF Capital's participation in Nanos Medical's (ENT diagnostic and treatment platform) Series D investment.
- Huagai Capital's lead investment in NK Cell Tech (NK cell therapy) in a Series A investment exceeding RMB 100 million.
- WeMed (high-end interventional diagnostic and therapeutic equipment) in its Series C+ financing of RMB 100 million led by Hillhouse Capital.
- Lake Bleu Capital's participation in late-stage equity investment.